Dasatinib inhibits proinflammatory functions of mature human neutrophils
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesDasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental SilicosisTargeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitroNeutrophil cell surface receptors and their intracellular signal transduction pathways.Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.The Lung is a Host Defense Niche for Immediate Neutrophil-Mediated Vascular Protection.The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patientsThe Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitmentNeutrophils are required for both the sensitization and elicitation phase of contact hypersensitivityThe role of dasatinib in the management of chronic myeloid leukemiaThe Src-Family Kinases Hck and Fgr Regulate Early Lipopolysaccharide-Induced Myeloid Cell Recruitment into the Lung and Their Ability To Secrete Chemokines.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Targeting inflammatory pathways in chronic lymphocytic leukemia.MASP-1 induces a unique cytokine pattern in endothelial cells: a novel link between complement system and neutrophil granulocytes.The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.Treatment recommendations for chronic myeloid leukemiaDefinition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.How I treat newly diagnosed chronic myeloid leukemia in 2015.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Regulation of Discrete Functional Responses by Syk and Src Family Tyrosine Kinases in Human NeutrophilsAdverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.2-Aminoxazole and 2-Aminothiazole Dasatinib Derivatives as Potent Inhibitors of Chronic Myeloid Leukemia K562 Cells.Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases.Drug conjugated nanoparticles activated by cancer cell specific mRNA.The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.Dasatinib-induced immunosuppression and recurrent respiratory tract infections.The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis.Phospholipid transfer protein and alpha-1 antitrypsin regulate Hck kinase activity during neutrophil degranulation
P2860
Q26749324-D3352CC6-0D27-497F-885D-89612BA18606Q26828782-DB995472-D4E8-4377-9581-4FC2F1486278Q27330347-0BFE67FE-D762-4E88-A35A-2CB2C3F57191Q28546317-B76AAC59-FC82-4032-8F41-19B00EB2BBB9Q30009577-AC45F23F-76A1-415F-BB88-B709E78869F3Q30278668-E190D082-36F5-4895-AD77-B7CB4A363A28Q30855831-91071DB1-8DCE-453B-9612-AD9E87FD2AC3Q33798573-C6E436FD-7DA0-42DD-A323-D741307F8BD4Q34230548-DFB12F62-4237-4103-8DC8-D2760B28065BQ34924724-502EA7CA-ABA0-40EA-A919-247243B5FF73Q35087994-A7A40969-9506-4BF1-8DFB-574E40025E44Q35988619-7D3794BA-E0B5-46EB-B9F0-CA884E5CC5B6Q37026032-DDA7945F-76AE-43E8-9F06-65495AF75256Q37351312-763429C3-CA6A-400D-BC1D-D02BCEBE95D9Q37529606-C64131A6-16AD-4E13-88B0-7CB891871BB5Q37686313-794CA7EC-47C3-4CF6-BCA1-73C3A0337D75Q37699569-78B3C75C-D079-479F-B323-93F399A9412CQ38181112-7D1A8C1F-6FAE-4970-B542-8BD5BBDFF14CQ38199143-6D52FE8C-7A61-4CAD-84E7-7254F851F4BBQ38265086-1811D2E3-A8E2-44B9-9BF8-B1828D02F3E5Q38457554-70F1318F-88B6-422E-8BE9-2EC4D8C1B0A9Q38682959-12E1A523-07A5-42FD-A1BC-0E75849299FEQ38707841-92EF7BBD-E9F9-4DA6-940B-0909B521D7F3Q38770334-DF291EE1-F508-46E5-8D80-B68347D1DB6EQ40053971-2EF728CB-0C17-4731-BB81-671CF3A961F0Q42363695-0E8B2199-7859-4541-93A7-832F0AC5A9BCQ43094413-4DA30ABA-CB29-4808-BFA0-641649D212D9Q43849289-33D1B52F-880A-4D46-8298-27BCA2BA6932Q54109924-583B2654-2778-4161-A501-7D87A2155EA4Q58603381-73DD47B8-A3A5-4A2D-B633-50815A27C715
P2860
Dasatinib inhibits proinflammatory functions of mature human neutrophils
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dasatinib inhibits proinflammatory functions of mature human neutrophils
@en
type
label
Dasatinib inhibits proinflammatory functions of mature human neutrophils
@en
prefLabel
Dasatinib inhibits proinflammatory functions of mature human neutrophils
@en
P2093
P2860
P1433
P1476
Dasatinib inhibits proinflammatory functions of mature human neutrophils
@en
P2093
Barbara Walzog
Krisztina Futosi
Robert Pick
Tamás Németh
Tibor Vántus
P2860
P304
P356
10.1182/BLOOD-2011-07-369041
P407
P577
2012-03-12T00:00:00Z